TY  - RPRT
TI  - Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
AU  - Chien-Ju Lin
AU  - James Wason
PY  - 2017
UR  - https://arxiv.org/abs/1703.00253
ID  - 1703.00253
ER  -